A Phase 1 interventional study of SHR-1314 in Axial Spondyloarthritis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-01-13.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Axial Spondyloarthritis with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Axial Spondyloarthritis · China.
Among the 16 studies in Axial Spondyloarthritis with a site in China, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2018, is the only one in phase 1, and was the 3rd registered.
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
Browse Axial Spondyloarthritis studies →6 of the 16 studies in Axial Spondyloarthritis with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18–45
China-Japan Friendship Hospital · Sites in China
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18+
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–65
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 274 across the 13 interventional studies, 247 across the 3 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
2 of the studies in Axial Spondyloarthritis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07133633Merck Sharp & Dohme LLCA Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | 2027-03-29 |
| NCT07724847Chinese PLA General HospitalMulticenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis | 2027-04-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Axial Spondyloarthritis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety, Tolerability and Pharmacokinetics (PK) of SHR1314 with axial spondyloarthritis.
This was a phase I, multicenter, double-blind, randomized, placebo-controlled study. The study originally planned to enroll 5 cohorts of 8 subjects each (N=40).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Multiple subcutaneous injections of SHR-1314 dose 1
Drug: SHR-1314
Multiple subcutaneous injections of SHR-1314 dose 2
Drug: SHR-1314
Multiple subcutaneous injections of SHR-1314 dose 3
Drug: SHR-1314
Multiple subcutaneous injections of SHR-1314 dose 4
Drug: SHR-1314
Multiple subcutaneous injections of SHR-1314 dose 5
Drug: SHR-1314
Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
Also known as: Placebo
The safety and tolerability of multiple subcutaneous injections of SHR1314 in adult patients with axial spondyloarthritis 1.Incidence of Treatment-Emergent Adverse Events 2.Incidence of Injection site reaction
Safety and tolerability of multiple subcutaneous injections of SHR1314 assessed by adverse events and serious adverse events. 1. Incidence of Treatment-Emergent Adverse Events 2. Incidence of Injection site reaction
Time frame: Baseline to 169 days after dose administration
Maximum observed serum concentration (Cmax) of SHR-1314
maximum concentration (Cmax)
Time frame: Baseline to 169 days after dose administration
Time to maximum observed serum concentration (tmax) of SHR-1314
Time to maximum concentration (Tmax)
Time frame: Baseline to 169 days after dose administration
Time to elimination half-life (t1/2) of SHR-1314
t1/2
Time frame: Baseline to 169 days after dose administration
Assessment of development of Anti-drug Antibodies (ADAs)
Incidence of development of Anti-drug Antibodies (ADAs)
Time frame: Baseline to 169 days after dose administration
Proportion of Participants Achieving an ASAS20 Response
ASAS20 Response
Time frame: Week2, 4, 6, 8, 12,16
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2018 to primary completion in Jan 2020, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vunakizumab
Jiangsu HengRui Medicine Co., Ltd. →